DOCS vs ZS
Doximity, Inc. and Zscaler, Inc., side by side — 7 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | DOCS | ZS |
|---|---|---|
| Revenue | $644.9M | $2.7B |
| Net income | $196.1M | $-41.5M |
| Gross margin | 89.1% | 76.9% |
| Net margin | 30.4% | −1.6% |
| Return on equity | 19.3% | −2.7% |
| Diluted EPS | $0.98 | −$0.27 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $326.5M | $808.2M |
| Equity | $950.8M | $1.8B |
| Net debt / equity | · | · |
| Current ratio | 6.09× | 2.01× |
| Revenue CAGR 5y | 25.5% | 44.0% |
| Profit CAGR 5y | 31.3% | · |
ZS bills 4.1× the revenue of DOCS, and ZS closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
7 years side by side
| Fiscal year | DOCS | ZS |
|---|---|---|
| FY2025 | $644.9M | $2.7B |
| FY2024 | $570.4M | $2.2B |
| FY2023 | $475.4M | $1.6B |
| FY2022 | $419.1M | $1.1B |
| FY2021 | $343.5M | $673.1M |
| FY2020 | $206.9M | $431.3M |
| FY2019 | $116.4M | $302.8M |
Bottom line
| Fiscal year | DOCS | ZS |
|---|---|---|
| FY2025 | $196.1M | $-41.5M |
| FY2024 | $223.2M | $-57.7M |
| FY2023 | $147.6M | $-202.3M |
| FY2022 | $112.8M | $-390.3M |
| FY2021 | $154.8M | $-262.0M |
| FY2020 | $50.2M | $-115.1M |
| FY2019 | $29.7M | $-28.7M |
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$2,028,252,000 | ZS |
| FY2024 | −$1,597,372,000 | ZS |
| FY2023 | −$1,141,530,000 | ZS |
| FY2022 | −$671,894,000 | ZS |
| FY2021 | −$329,552,000 | ZS |
| FY2020 | −$224,372,000 | ZS |
| FY2019 | −$186,448,000 | ZS |
ZS has reported the higher revenue in every one of these 7 fiscal years. The gap has widened since the earliest year compared.
7 of 10 comparable fiscal years — a year missing data on either side is not counted.
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +32.0 pp | DOCS |
| FY2024 | +41.8 pp | DOCS |
| FY2023 | +43.6 pp | DOCS |
| FY2022 | +62.7 pp | DOCS |
| FY2021 | +84.0 pp | DOCS |
| FY2020 | +51.0 pp | DOCS |
| FY2019 | +35.0 pp | DOCS |
DOCS has kept the higher net margin in every one of these 7 fiscal years.
7 of 10 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ZS's net margin has been more volatile than DOCS's over the 7 comparable fiscal years — 14.3 percentage points of standard deviation against 7.1.
7 of 10 comparable fiscal years — a year missing data on either side is not counted.
Year by year
DOCS led in net margin in every one of the 7 comparable fiscal years — a structural lead, not a recent swing.
7 of 10 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
DOCS's return on equity has been more volatile than ZS's over the 7 comparable fiscal years — 902.5 percentage points of standard deviation against 23.4.
7 of 7 comparable fiscal years — a year missing data on either side is not counted.
Year by year
DOCS led in return on equity in every one of the 7 comparable fiscal years — a structural lead, not a recent swing.
7 of 7 comparable fiscal years — a year missing data on either side is not counted.